clinical trial · NCT03721978
REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
Cervical DysplasiaCervical High Grade Squamous Intraepithelial LesionHSILVGX-3100Matched PlaceboCELLECTRA™-5PSP
brief summary
HPV-303 is a prospective, randomized, double-blind, placebo-controlled study of VGX-3100 delivered intramuscularly (IM) followed by electroporation (EP) delivered with CELLECTRA™ 5PSP in adult women with histologically confirmed high-grade squamous intraepithelial lesions (HSIL) (cervical intraepithelial neoplasia grade 2 \[CIN2\] or grade 3 \[CIN3\]) of the cervix, associated with human papillomavirus (HPV-16) and/or HPV-18.
started
Feb 28, 2019
primary completion
Aug 23, 2022
completion
Sep 15, 2022
last updated
Oct 17, 2024
official title
A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™ 5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol